Clinical Study | Number of Participants | LOF | Evidence Level | Publication |
Feasibility study | 26 | 3 mo | II-1 | Deckers et al 2015145 |
ReActiv8-A | 53 | 12 mo | II-1 | Deckers et al 2018146 |
48 mo | II-1 | Mitchell et al 2021147 | ||
ReActiv8- PMCF | 37 | 24 mo | II-1 | Thomson et al 2021148 |
36 mo | II-1 | Thomson et al 2023149 | ||
ReActiv8-B | 204 | 120 d/12 mo | I/II | Gilligan et al 2021150 |
24 mo | II-1 | Gilligan et al 2022151 | ||
36 mo | II-1 | Gilligan et al 2022152 | ||
48 mo | N/A | Gilligan et al153 | ||
Subanalysis | II-1 | Shaffrey et al 2022135 | ||
ReActiv8-C | 41 | 12 mo | II-1 | Ardeshiri et al 2022154 |
Abbreviation: LOF, length of follow-up.